Masimo Announces Select Preliminary 2023 Financial Results and 2024 Guidance

Rhea-AI Summary

Masimo Corporation (MASI) announced preliminary financial results for Q4 and full-year 2023, with consolidated revenue of $541-551 million for Q4 and $2,041-2,051 million for full-year 2023. Full-year 2024 guidance includes consolidated revenue of $2,045-2,165 million, with updated non-GAAP earnings per diluted share of $3.44-3.60.

Positive

• Consolidated revenue for Q4 and full-year 2023 is strong, indicating positive growth.
• Full-year 2024 guidance shows an optimistic outlook for Masimo's financial performance.
• The update to non-GAAP financial measures is expected to provide more useful information to investors.

Negative

• The impact of all expenses related to litigation against Apple will be excluded from non-GAAP financial measures, potentially skewing the financial performance data.
• The exclusion of litigation expenses could obscure the actual operating performance of the company.

Financial Analyst

Masimo Corporation's preliminary financial results and guidance for the upcoming year provide valuable insights into the company's performance and trajectory. An analysis of the provided revenue figures shows a stable growth trend, with the healthcare segment contributing significantly to the consolidated revenue. The projected non-healthcare revenue indicates diversification, which could potentially mitigate sector-specific risks. The increase in GAAP earnings per diluted share from 2023 to 2024 suggests improved profitability. However, the range of non-GAAP earnings per diluted share, especially with the updated definition excluding all litigation expenses against Apple, reflects a significant adjustment. Investors should scrutinize the underlying reasons for these adjustments to better assess the company's operational efficiency and real earnings potential. Furthermore, the exclusion of litigation costs from non-GAAP measures may raise questions about the transparency and comparability of reported earnings, necessitating a careful evaluation of these non-operational expenses.

Legal Expert

The decision to update non-GAAP financial measures to exclude all expenses related to litigation against Apple represents a strategic shift in Masimo's financial reporting. This move aligns with the company's belief that these expenses are non-recurring and not reflective of ongoing operations. From a legal perspective, it is essential to consider the nature of the litigation, its potential impact on the company's future operations and the precedent it sets for financial reporting practices. Investors and analysts should be aware that while this approach may provide a cleaner view of the company's core performance, it also removes a potentially material financial burden from the operational assessment. The reconciliation of GAAP to non-GAAP measures provided by the company is a critical tool for stakeholders to understand the adjustments made and to evaluate the company's financial health accurately.

Market Research Analyst

The guidance provided for full-year 2024 indicates a cautious yet optimistic outlook from Masimo Corporation. The forecasted consolidated revenue range shows a potential for growth, which is a positive signal for stakeholders. However, the broader range for non-healthcare revenue suggests uncertainty in this segment, possibly due to fluctuating market conditions or strategic pivots. It is crucial for market analysts to monitor industry trends and competitor performance to contextualize Masimo's projections. Additionally, the updated non-GAAP earnings per diluted share may reflect management's confidence in the company's core business, excluding litigation costs, which could be perceived as a one-time expense. Nevertheless, stakeholders should consider the broader economic environment, including healthcare spending trends and regulatory changes, when evaluating the company's prospects.

Complete fourth quarter and full-year 2023 financial results will be announced on Tuesday, February 27, 2024

IRVINE, California--(BUSINESS WIRE)-- Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance.

Preliminary Fourth Quarter 2023 Financial Results:

	•		Consolidated revenue of $541 million to $551 million;
	•		Healthcare revenue of $336 million to $341 million; and
	•		Non-healthcare revenue of $205 million to $210 million.

Preliminary Full-Year 2023 Financial Results:

	•		Consolidated revenue of $2,041 million to $2,051 million;
	•		Healthcare revenue of $1,272 million to $1,277 million; and
	•		Non-healthcare revenue of $769 million to $774 million.

The preliminary financial information presented in this press release is based on Masimo’s current expectations and may be adjusted as a result of, among other things, completion of customary annual audit procedures. Management plans to discuss Masimo’s complete fourth quarter and full-year 2023 financial results after the market closes on Tuesday, February 27, 2024.

Full-Year 2024 Guidance:

	•		Consolidated revenue of $2,045 million to $2,165 million;
	•		Healthcare revenue of $1,345 million to $1,385 million;
	•		Non-healthcare revenue of $700 million to $780 million;
	•		GAAP earnings per diluted share of $1.91 to $2.08;
	•		Non-GAAP earnings per diluted share of $3.00 to $3.15 (prior definition); and
	•		Non-GAAP earnings per diluted share of $3.44 to $3.60 (updated definition).

Effective fiscal year 2024, we are updating our non-GAAP financial measures to exclude the impact of all expenses related to our litigation against Apple. Masimo had previously only excluded the expenses related to the U.S. International Trade Commission litigation against Apple. Masimo believes all of the Apple litigation expenses are unique in nature and not indicative of the Company’s on-going operating performance and is therefore excluding them from its non-GAAP financial measures. The Company has included a reconciliation of its non-GAAP financial measures under both the updated and prior definitions to assist investors in making comparisons of period-to-period operating results.

		Full-Year 2024 Guidance
				(Updated Definition)		(Prior Definition)
(in millions, except earnings per diluted share)		GAAP		Non-GAAP		Non-GAAP
Consolidated revenue		$2,045 to $2,165		$2,045 to $2,165		$2,045 to $2,165
Healthcare revenue		$1,345 to $1,385		$1,345 to $1,385		$1,345 to $1,385
Non-healthcare revenue		$700 to $780		$700 to $780		$700 to $780
Consolidated operating income		$198 to $214		$307 to $322		$275 to $290
Consolidated earnings per diluted share		$1.91 to $2.08		$3.44 to $3.60		$3.00 to $3.15

Supplementary Non-GAAP Financial Information

For additional non-GAAP financial details, please visit the Investor Relations section of the Company’s website at www.masimo.com to access Supplementary Financial Information.

Non-GAAP Financial Measures

The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with U.S. GAAP. The non-GAAP financial measures presented exclude the items described below. Management uses these non-GAAP financial measures internally for its operating and budgeting purposes, and believes that adjustments for these items assist investors in making comparisons of period-to-period operating results. Furthermore, management believes that the excluded items are not indicative of the Company’s on-going operating performance. These non-GAAP financial measures have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as determined in accordance with GAAP.

Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.

The Company has presented the following non-GAAP measures to assist investors in understanding the Company’s net operating results on an on-going basis: (i) constant currency revenue growth %, (ii) non-GAAP net income, (iii) non-GAAP (net income) earnings per diluted share and (iv) non-GAAP operating income/margin. These non-GAAP financial measures may also assist investors in making comparisons of the Company’s operating results with those of other companies. Management believes constant currency revenue growth, non-GAAP operating income/margin, non-GAAP net income and non-GAAP earnings per diluted share are important measures in the evaluation of the Company’s performance and uses these measures to better understand and evaluate our business.

The non-GAAP financial measures reflect adjustments for the following items:

Constant currency revenue adjustments

Some of our sales agreements with foreign customers provide for payment in currencies other than the U.S. Dollar. These foreign currency revenues, when converted into U.S. Dollars, can vary significantly from period-to-period depending on the average and quarter-end exchange rates during a respective period. We believe that comparing these foreign currency denominated revenues by holding the exchange rates constant with the prior year period is useful to management and investors in evaluating our revenue growth rates on a period-to-period basis. We anticipate that fluctuations in foreign exchange rates and the related constant currency adjustments for calculation of our revenue growth rate will continue to occur in future periods.

Acquired tangible asset amortization

These transactions represent amortization expense in connection with business or assets acquisitions associated with acquired tangible assets and asset valuation step-ups.

Acquired intangible asset amortization

These transactions represent amortization expense in connection with business or assets acquisitions associated with acquired intangible assets including, but not limited to customer relationships, intellectual property, trade names and non-competition agreements.

Acquisition, integration and related costs

These transactions represent gains, losses, and other related costs associated with acquisitions, integrations, investments, divestitures, assets impairments, and in-process research and development.

Business transition and related costs

These transactions represent gains, losses, and other related costs associated with business transition plans. These items may include but are not limited to severance, relocation, consulting, leasehold exit costs, asset impairment, and other related costs to rationalize our operational footprint and optimize business results.

Litigation related expenses and settlements (prior definition)

These transactions represent gains, losses, and other related costs associated with certain litigation matters, which can vary in their characteristics, frequency and significance to our operating results.

Litigation related expenses and settlements (updated definition)

We have been engaged in various legal proceedings against Apple since January 2020, including various proceedings in the federal courts, various proceedings in the U.S. Patent and Trademark Office (the “PTO proceedings”), and a proceeding in the U.S. International Trade Commission (the “ITC proceeding”). Although we previously excluded only expenses relating to the ITC proceeding from the definition of “Litigation related expenses and settlements”, beginning with the first quarter of 2024, we have revised the definition of “Litigation related expenses and settlements” to exclude not only expenses relating to the ITC proceeding, but also all other Apple litigation expenses, including those relating to the federal court proceedings and the PTO proceedings. We believe all of the Apple litigation expenses are unique in nature and not indicative of the Company’s on-going operating performance, and this updated definition will provide more useful information to investors by facilitating period-to-period comparisons of our financial performance that otherwise may be obscured by the significant fluctuations in Apple-related litigation expenses.

Other adjustments

In the event there are gains, losses and other adjustments which impact period-to-period comparability and do not represent the underlying ongoing results of the business, the Company may choose to exclude these from non-GAAP earnings.

Financing related adjustments

The Company may enter into various financial arrangements whereby costs are incurred and certain instrument features are valued and expensed accordingly but are not necessarily indicative of the on-going cash flow generation of the Company and therefore excludes these costs from non-GAAP earnings. For GAAP earnings per diluted share purposes, the Company cannot reflect the anti-dilutive impact, if applicable, in its diluted shares calculations. However, the Company believes that reflecting the anti-dilutive impact of these instruments in non-GAAP earnings per diluted share provides management and investors with useful information in evaluating the financial performance of the Company on a per share basis.

Realized and unrealized gains or losses

These transactions represent gains, losses, and other related costs associated with foreign currency denominated transactions and investments. Changes in the underlying currency rates relative to the U.S. Dollar may result in realized and unrealized foreign currency gains and losses between the time these receivables and payables arise and the time that they are settled in cash. Unrealized and realized gains and losses on investments may impact the Company’s reported results of operations for a period. These items are highly variable, difficult to predict and outside the control of those responsible for the underlying operations of the business. Other items also included here are mark-to-market gains and losses of derivative contracts that are not designated as hedging instruments or the ineffective portions of cash flow hedges.

Tax impact of non-GAAP adjustments

In order to reflect the tax effected impact of the non-GAAP adjustments, the Company will adjust the non-GAAP earnings by the approximate tax impact of these adjustments.

Excess tax benefits from stock-based compensation expense

GAAP requires that excess tax benefits recognized on stock-based compensation expense be reflected in our provision for income taxes rather than paid-in capital. As these excess tax benefits may be highly variable from period-to-period, the Company may choose to exclude these tax benefits from non-GAAP earnings to facilitate comparability between periods and with peers.

RECONCILIATION OF GAAP TO NON-GAAP CONSOLIDATED OPERATING INCOME(1):
(in millions)			Full-Year 2024 Guidance(2)		Full-Year 2023 Guidance(3)
GAAP Operating Income			$198 to $214		$ 138 to $152
	Non GAAP Adjustments:
	Acquired tangible asset amortization		6		6
	Acquired intangible asset amortization		37		38
	Acquisition, integration and related costs		7		20
	Business transition and related costs		12		4
	Litigation related expenses and settlements		14		45
	Other adjustments		—		4
Non-GAAP Operating Income (prior definition)			$275 to $290		$256 to $270
	Litigation related expenses and settlements(4)		32		38
Non-GAAP Operating Income (updated definition)			$307 to $322		$294 to $308

__________________

⁽¹⁾ May not foot due to rounding.
⁽²⁾ Guidance provided January 10, 2024.
⁽³⁾ Guidance provided on November 7, 2023.
⁽⁴⁾ Adjustments to conform to the new updated non-GAAP definition which excludes all Apple-related litigation expenses.

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET INCOME PER DILUTED SHARE(1):
			Full-Year 2024 Guidance(2)				Full-Year 2023 Guidance(3)
(in thousands, except per share amounts)			$		Per Diluted Share		$		Per Diluted Share
GAAP net income			$105 to $115		$1.91 to $2.08		$72 to $83		$1.34 to $1.54
Non-GAAP adjustments:
	Acquired tangible asset amortization		6		0.12		6		0.12
	Acquired intangible asset amortization		37		0.68		38		0.70
	Acquisition, integration and related costs		7		0.12		20		0.36
	Business transition and related costs		12		0.22		4		0.08
	Litigation related expenses and settlements		14		0.24		45		0.83
	Other adjustments		—		—		4		0.07
	Realized and unrealized gains or losses		—		—		(7)		(0.12)
	Financing related adjustments		2		0.03		2		0.03
	Tax impact of non-GAAP adjustments		(16) to (17)		(0.30) to (0.31)		(27)		(0.50)
	Excess tax benefits from stock-based compensation		(2)		(0.03)		(4)		(0.07)
Non-GAAP net income (prior definition)			$165 to $174		$3.00 to $3.15		$155 to $165		$2.85 to $3.05
	Litigation related expenses and settlements(4)		32		0.58		38		0.71
	Tax impact of non-GAAP adjustments		(8)		(0.14)		(9)		(0.17)
Non-GAAP net income (updated definition)			$189 to $198		$3.44 to $3.60		$184 to $195		$3.39 to $3.59
Weighted average shares outstanding - diluted					55.1				54.2

__________________

⁽¹⁾ May not foot due to rounding.
⁽²⁾ Guidance provided January 10, 2024.
⁽³⁾ Guidance provided on November 7, 2023.
⁽⁴⁾ Adjustments to conform to the new updated non-GAAP definition which excludes all Apple-related litigation expenses.

Conference Call:

The conference call to review Masimo’s complete fourth quarter and full-year 2023 financial results will begin at 1:30 p.m. PT (4:30 p.m. ET) on Tuesday, February 27, 2024 and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.masimo.com.

To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID number.

Conference Call Registration Link:

https://conferencingportals.com/event/nUSpRIEm

A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About Masimo

Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight iconic audio brands, including Bowers & Wilkins^®, Denon^®, Marantz^®, and Polk Audio^®. Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion^™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet^™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll. In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively and intermittently, including total hemoglobin (SpHb^®), oxygen content (SpOC^™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (Pvi^®), RPVi^™ (rainbow^® Pvi), and Oxygen Reserve Index (Ori^™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA^™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^®, Radius-PPG^® and Radius VSM^™, portable devices like Rad-67^®, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^®. Masimo hospital and home automation and connectivity solutions are centered around Root and the Masimo Hospital Automation^™ platform, and include Iris^® Gateway, iSirona^™, Patient SafetyNet, Replica^®, Halo ION, UniView^®, UniView :60^™, and Masimo SafetyNet^™. Masimo’s growing portfolio of health and wellness solutions include Radius T^™ and the Masimo W1^™ watch, Stork^™, Opioid Halo™, Bridge^™, and PerL^™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

RPVi has not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including our expectations regarding our updated fourth-quarter and full-year 2023 preliminary financial results and full-year 2024 guidance, including consolidated revenue, healthcare revenue, non-healthcare revenue, consolidated operating income and consolidated GAAP and non-GAAP earnings per diluted share. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: completion of customary annual audit procedures for our 2023 financial statements; our dependence on Masimo SET^® and Masimo rainbow SET^™ products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; our ability to successfully integrate Sound United’s brands into our business; our ability to address and expand into new markets; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; our ongoing litigation and related matters; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240110665066/en/

Investor Contact: Eli Kammerman

(949) 297-7077

ekammerman@masimo.com

Media Contact: Evan Lamb

(949) 396-3376

elamb@masimo.com

Source: Masimo Corporation

FAQ

What are Masimo Corporation's (MASI) preliminary financial results for Q4 and full-year 2023?

The preliminary financial results for Q4 2023 include consolidated revenue of $541-551 million, while full-year 2023 saw consolidated revenue of $2,041-2,051 million.

What is Masimo Corporation's (MASI) full-year 2024 guidance for consolidated revenue and non-GAAP earnings per diluted share?

The full-year 2024 guidance includes consolidated revenue of $2,045-2,165 million and updated non-GAAP earnings per diluted share of $3.44-3.60.

What is the impact of the update to non-GAAP financial measures for Masimo Corporation (MASI)?

The update will exclude all expenses related to litigation against Apple from non-GAAP financial measures, potentially affecting the comparability of period-to-period operating results.

Where can I find additional non-GAAP financial details for Masimo Corporation (MASI)?

For additional non-GAAP financial details, please visit the Investor Relations section of the Company’s website at www.masimo.com to access Supplementary Financial Information.

When will Masimo Corporation (MASI) discuss its complete fourth quarter and full-year 2023 financial results?

Management plans to discuss Masimo’s complete fourth quarter and full-year 2023 financial results after the market closes on Tuesday, February 27, 2024.